Clinical trials: Body Weight Control
Overweight and Obesity
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity
The aim of this trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS9531 injection compared with placebo in adolescents with obesity
- Trial name
- NCT07559136
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity
Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity
To assess the safety and tolerability of AMG 171 as single or multiple doses in subjects with obesity
- Trial name
- NCT04199351
- Testing
- AMG 171
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Amgen
Obesity
A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity
The main objective of this trial is to investigate the effect of BI 1820237 alone, BI 456906 alone, combination of BI 1820237 and BI 456906 versus placebo on brain activity.
- Trial name
- NCT06352424
- Testing
- BI 456906, BI 1820237
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- Boehringer Ingelheim
Obesity
To Assess the Safety, Tolerability, Pharmacokinetics and Pharmakodynamics of AZD2820 After Multiple Ascending Doses
This is a randomised and single-blind, placebo-controlled study to investigate the safety, tolerabilty, pharmacokinetics and pharmacodynamics of repeated and ascending doses of AZD2820 to obese but otherwise healthy male subjects.
- Trial name
- NCT01469923
- Testing
- AZD2820
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Obesity
A Study to Evaluate ALN-2232 in Participants With Obesity
The purpose of this study is to: evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity evaluate the safety, tolerability…
- Trial name
- NCT07463846
- Testing
- ALN-2232, Tirzepatide
- Where
- Canada
- Volunteers
- 156 people
- Sponsor
- Alnylam Pharmaceuticals
Obesity
A 2-Year Study of an Investigational Drug in Obese Patients (0557-011)
This is a 2-year study to assess the safety, tolerability, and efficacy of an investigational drug in obese patients.
- Trial name
- NCT00092859
- Testing
- MK0557
- Volunteers
- 1,500 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity
Pharmacokinetics, Safety, Tolerability and Efficacy of Intravenous Doses of ZGN-433 in Obese Female Volunteers
The purpose of this study is to assess whether multiple doses of ZGN-433 are safe and effective.
- Trial name
- NCT01372761
- Testing
- ZGN-433, Normal Saline
- Where
- Australia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Zafgen, Inc.
Normal Healthy Adults
A Research Study to Evaluate BLX-0871 in Healthy Adults
This study will test an oral medicine called BLX-0871, which is being developed to improve metabolic health by activating AMP-activated protein kinase (AMPK), a key regulator of energy balance.
- Trial name
- NCT07140081
- Testing
- BLX-0871
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Biolexis Therapeutics
Metabolism and Nutrition Disorder, Obesity
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America. The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese…
- Trial name
- NCT01272219
- Testing
- liraglutide
- Where
- 226 sites in United States, Argentina and 27 more
- Volunteers
- 3,731 people
- Sponsor
- Novo Nordisk A/S
Cachexia
SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)
To evaluate SUN11031 for subcutaneous injection compared to placebo in subjects with cachexia associated with Chronic Obstructive Pulmonary Disease (COPD) to determine the effect on physical performance and body composition.
- Trial name
- NCT00698828
- Testing
- SUN11031 20 μg/kg, SUN11031 40 μg/kg
- Where
- 43 sites in United States, Argentina and 4 more
- Volunteers
- 227 people
- Sponsor
- Daiichi Sankyo
Overweight or Obesity
To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese
The study aims to evaluate the efficacy and safety of HRS9531 in subjects with overweight or obese for 48 weeks.
- Trial name
- NCT06396429
- Testing
- HRS9531 injection
- Where
- China
- Volunteers
- 567 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Functional Gastrointestinal Disorders (FGIDs), Weight Loss
Effects of Multi-strain Bacillus Spore Probiotics on Growth, Digestive Function, and Gut Microbiota in Cesarean-Delivered Neonates
Infants born by cesarean section commonly show early weight loss and slower recovery of birth weight, together with characteristic patterns of gut microbiota dysbiosis marked by reduced Bifidobacterium and Bacteroides and…
- Trial name
- NCT07320287
- Testing
- RO water, LiveSpo PREG-MOM, LiveSpo CONSY
- Where
- Vietnam
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Anabio R&D
Satiety, Appetite Regulation
A Placebo-Controlled Study Evaluating the Effects of Arrabina on Satiety in Healthy Adults
This study is being conducted to assess the effects of a prebiotic product, Arrabina, on appetite in healthy adults. The goal is to see if this product can help with appetite regulation, support gut health, and support weight…
- Conditions
- Satiety, Appetite Regulation, Weight Control
- Trial name
- NCT06884449
- Testing
- Arrabina Prebiotic 5.0 g, Arrabina Prebiotic 3.5 g
- Where
- 3 sites in United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Comet Bio Inc.
Overweight, Healthy Subjects
First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects
Primary Objective: To assess the safety and tolerability of SAR441255 after ascending single subcutaneous (SC) doses Secondary Objectives: To assess the pharmacokinetic parameters of SAR441255 in plasma after ascending single SC…
- Trial name
- NCT04521738
- Testing
- SAR441255
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Sanofi
Overweight or Obesity
A Study of ZT002 Injection With Subjects With Overweight or Obesity
This study will evaluate the percentage change from baseline in weight after 24 weeks of treatment with ZT002 Injection in subjects with overweight/obesity.
- Trial name
- NCT07020884
- Testing
- ZT002 Injection
- Where
- 16 sites in China
- Volunteers
- 303 people
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Obesity
A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease
The main purpose of this study is to learn more about tirzepatide in participants with obesity disease. The study will also measure how Tirzepatide affects body weight with a low-calorie diet and increased physical activity.
- Trial name
- SURMOUNT-J (NCT04844918)
- Testing
- Tirzepatide
- Where
- 18 sites in Japan
- Volunteers
- 267 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics, of multiple oral doses…
- Conditions
- Obesity, Overweight, Healthy
- Trial name
- NCT00959426
- Testing
- PF-04620110
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes
SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary
Participant will get oral semaglutde as prescribed by the study doctor. The study will last for about 26 ± 4 weeks (5 to 7 months).
- Trial name
- NCT06269120
- Testing
- Oral Semaglutide
- Where
- 19 sites in Hungary
- Volunteers
- 243 people
- Sponsor
- Novo Nordisk A/S
Osteoarthritis in the Knee, Obesity
Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis
The goal of this clinical trial is to learn if KBP-336 works to treat pain in osteoarthritis in individuals living with obesity.
- Trial name
- NCT06833749
- Testing
- KBP-336
- Where
- 20 sites in Czechia, Denmark and 4 more
- Volunteers
- 600 people
- Sponsor
- KeyBioscience AG
Migraine, Ketogenic Dieting
Th Effect of Ketogenic Metabolic Nutritional Pattern on High-frequency Episodic Migraine (EMIKETO)
The study aims to investigate the impact of 2 nutritional patterns on high-frequency episodic migraine. Subjects enrolled will be randomized in two arms: a) very-low-calorie-ketogenic-diet (VLCKD), b) hypocaloric balanced non…
- Conditions
- Migraine, Ketogenic Dieting, Weight Loss, Overweight
- Trial name
- EMIKETO (NCT04360148)
- Testing
- very-low-calorie-ketogenic-diet, hypocaloric-balanced-diet
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- New Penta SRL